Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2019
2019 World Conference on Lung Cancer
Access to all presentations that occur during the 2019 World Conference on Lung Cancer in Barcelona, Spain
Presentation Date(s):- Sept 7 - 10, 2019
- Total Presentations: 2848
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
JCSE01 - Joint IASLC-CSCO-CAALC Session
- Type: Joint IASLC-CSCO-CAALC Session
- Track:
- Presentations: 11
- Now Available
- Moderators:Chunxue Bai
- Coordinates: 9/07/2019, 07:00 - 11:15, Toronto (1985)
-
+
JCSE01.01 - Breakfast and Poster Viewing
07:00 - 07:30
- Abstract
No abstract available for this presentation
-
+
JCSE01.02 - The Opportunity of Drugs Development on Immunotherapy in China (Now Available)
07:30 - 07:50 | Presenter: Qing Zhou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.03 - Any Difference on Efficacy and Toxicity Between East and West? (Now Available)
07:50 - 08:10 | Presenter: Jie Hu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.04 - Neo-Adjuvant Immunotherapy in Lung Cancer (Now Available)
08:10 - 08:30 | Presenter: Nan Wu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.05 - Biomarker in Immunotherapy: Myth or Reality? (Now Available)
08:30 - 08:50 | Presenter: Alfredo Addeo
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.06 - New Era Beyond PD-1/PD-L1 (Now Available)
08:50 - 09:10 | Presenter: Luis Paz-Ares
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.07 - Discussion (Now Available)
09:10 - 09:20
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.08 - Coffee Break and Poster Viewing
09:20 - 09:45
- Abstract
No abstract available for this presentation
-
+
JCSE01.09 - A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:55 | Presenter: Yi-Long Wu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.10 - Efficacy and Safety of Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Non-Small Cell Lung Cancer (Now Available)
09:55 - 10:05 | Author(s): Ning Li
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.11 - Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) (Now Available)
10:05 - 10:15 | Presenter: Baohui Han
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.12 - Discussant Oral Abstracts (Now Available)
10:15 - 10:30 | Presenter: Bob T Li
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.13 - Discussant Poster Abstracts (Now Available)
10:30 - 10:45 | Presenter: Shun Lu
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE01.14 - Higher Prevalence of EGFR Mutations Significantly Correlates with Lower PD-L1 Expression in Chinese Lung Adenocarcinoma
10:45 - 10:45 | Author(s): Shiwang Wen
- Abstract
Loading... -
+
JCSE01.15 - Liver Metastases Predicts Poorer Prognosis in Advanced NSCLC Patients Who Receiving Nivolumab Monotherapy
10:45 - 10:45 | Presenter: Guowei Zhang
- Abstract
Loading... -
+
JCSE01.16 - Metastatic Lymph Nodes as High Immunogenicity Media for Perioperative Immunotherapy in Locally Advanced NSCLC
10:45 - 10:45 | Presenter: Chao Zhang
- Abstract
Loading... -
+
JCSE01.17 - Modelling the Immunosuppressive Difference of SBRT and CRT by Simulating the Dose to Circulating Lymphocytes in Non-Small Cell Lung Cancer
10:45 - 10:45 | Author(s): Yichao Shen
- Abstract
Loading... -
+
JCSE01.18 - A CT-Based Radiomics Approach to Predict PD1 Inhibitor Response in Non-Small-Cell Lung Cancer
10:45 - 10:45 | Presenter: Jialei Wang
- Abstract
Loading... -
+
JCSE01.19 - Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer
10:45 - 10:45 | Presenter: Yuan Li
- Abstract
Loading... -
+
JCSE01.20 - Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
10:45 - 10:45 | Author(s): Wei Zhang
- Abstract
Loading... -
+
JCSE01.21 - Changes of Peripheral Blood sPD-L1 in Patients with Small Cell Lung Cancer During Chemotherapy and Its Clinical Significance
10:45 - 10:45 | Presenter: Hao Tian
- Abstract
Loading... -
+
JCSE01.22 - Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer
10:45 - 10:45 | Author(s): Kai Yin
- Abstract
Loading... -
+
JCSE01.23 - Specific TP53 Mutation Subtypes as Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC
10:45 - 10:45 | Presenter: Hao Sun
- Abstract
Loading... -
+
JCSE01.24 - Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
10:45 - 10:45 | Presenter: Jianguo Sun
- Abstract
Loading... -
+
JCSE01.25 - TP53/KMT2C Co-Mutation as a Novel Biomarker for Immunotherapy in Non-Small Cell Lung Cancer Patients
10:45 - 10:45 | Presenter: Qing Zhou
- Abstract
Loading... -
+
JCSE01.26 - PD-1 Inhibitor Plus Chemotherapy as 2nd/Subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC
10:45 - 10:45 | Presenter: Shengxiang Ren
- Abstract
Loading... -
+
JCSE01.28 - Changes of Brain Structure in Advanced NSCLC Patients Receiving EGFR-TKIs: Dynamic Analysis Based on Series MRI Images
10:45 - 10:45 | Presenter: Chunli Luo
- Abstract
Loading...
-
+
EP1.14 - Targeted Therapy
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.14-49 - A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Exploratory Biomarker Analysis (Now Available)
08:00 - 08:00 | Presenter: Jie Wang
- Abstract
Loading...
-
+
P1.01 - Advanced NSCLC
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.01-28 - Mutational Heterogeneity Between Primary Pulmonary Cancer Lesions and Matched Brain Metastases (Now Available)
09:45 - 09:45 | Presenter: Linlin link Li
- Abstract
Loading... -
+
P1.01-61 - A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P1.01-81 - A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients with Lung Cancer
09:45 - 09:45 | Presenter: Wenfang Tang
- Abstract
Loading... -
+
P1.01-82 - The Different Frequencies and Genetic Profiles of Histologic Transformation After Different EGFR-TKIs in EGFR-Mutant Adenocarcinomas
09:45 - 09:45 | Presenter: Jin Kang
- Abstract
Loading... -
+
P1.01-85 - Treatment for Advanced NSCLC with EGFR Mutations and De Novo MET Amplification/Overexpression
09:45 - 09:45 | Presenter: Han-Min Wang
- Abstract
Loading... -
+
P1.01-104 - Survivals in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer Treated with First-Line Crizotinib
09:45 - 09:45 | Presenter: Yu-Er Gao
- Abstract
Loading...
-
+
P1.04 - Immuno-oncology
- Type: Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.04-42 - Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer (Now Available)
09:45 - 09:45 | Author(s): Kai Yin
- Abstract
Loading...
-
+
P1.14 - Targeted Therapy
- Type: Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
- Presentations: 2
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.14-13 - EGFR Amplification Mediates Resistance to Third-Generation EGFR TKIs and in Vitro Validation of Combination Strategies to Overcome Resistance (Now Available)
09:45 - 09:45 | Presenter: Yi-Chen Zhang
- Abstract
Loading... -
+
P1.14-31 - Lack of Association Between BIM Deletion Polymorphism and Clinical Efficacy of EGFR-TKIs in NSCLC Based on NGS (Now Available)
09:45 - 09:45 | Presenter: Si-Yang Liu
- Abstract
Loading... -
+
P1.14-39 - Acquired ALK Rearrangement in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR TKIs
09:45 - 09:45 | Presenter: Qian-Yu Wang
- Abstract
Loading... -
+
P1.14-62 - Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Combined Analysis of Two Single-Arm Phase IIIb Studies
09:45 - 09:45 | Author(s): Filippo De Marinis
- Abstract
Loading...
-
+
MA09 - EGFR & MET
- Type: Mini Oral Session
- Track: Targeted Therapy
- Presentations: 1
- Now Available
- Moderators:Jordi Remon
- Coordinates: 9/08/2019, 15:15 - 16:45, Melbourne (1991)
-
+
MA09.09 - Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18‑Month Follow-Up (Now Available)
16:15 - 16:20 | Presenter: Yi-Long Wu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MS04 - New Systemic Adjuvant/Neo-Adjuvant Strategies in Early Stage Lung Cancer: Targeted Therapy and I/O
- Type: Mini Symposium
- Track: Treatment of Early Stage/Localized Disease
- Presentations: 1
- Now Available
- Moderators:Eldsamira Mascarenhas
- Coordinates: 9/08/2019, 15:15 - 16:45, Hilton Head (1978)
-
+
MS04.01 - EGFR TKIs for Resected EGFRmut NSCLC (Now Available)
15:15 - 15:30 | Presenter: Yi-Long Wu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.01 - Advanced NSCLC
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 0
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.01-79 - Afatinib in EGFR Mutation-Positive (EGFRm+) NSCLC Harbouring Uncommon Mutations: Experience in ‘Real-World’ Clinical Practice
10:15 - 10:15 | Author(s): Wolfgang Brückl
- Abstract
Loading... -
+
P2.01-80 - Clinical Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs Followed by Subsequent Osimertinib
10:15 - 10:15 | Presenter: Yi-Hui Yao
- Abstract
Loading... -
+
P2.01-88 - Molecular Alterations in Cerebrospinal Fluid Predict Clinical Outcomes of Central Nervous System Metastases in Lung Cancer
10:15 - 10:15 | Presenter: Meimei Zheng
- Abstract
Loading... -
+
P2.01-99 - A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis
10:15 - 10:15 | Presenter: Yi-Long Wu
- Abstract
Loading...
-
+
P2.03 - Biology
- Type: Poster Viewing in the Exhibit Hall
- Track: Biology
- Presentations: 0
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.03-32 - Metastatic Lymph Nodes as High Immunogenicity Media for Perioperative Immunotherapy in Locally Advanced NSCLC
10:15 - 10:15 | Presenter: Chao Zhang
- Abstract
Loading...
-
+
P2.04 - Immuno-oncology
- Type: Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Now Available
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.04-38 - Tumor-Associated Neutrophils as a Potential Predictor for Early Recurrence in Resectable I-IIIA Lung Adenocarcinoma (Now Available)
10:15 - 10:15 | Presenter: Xue-Tao Li
- Abstract
Loading...